| Updated in 8/12/2020 12:05:31 PM |
Viewed: 297 times |
(Journal Article) |
Pigment cell & melanoma research 27 (2): 263-74 (2014)
Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.
Brian A Wall
,
Janet Wangari-Talbot
,
Seung S Shin
,
Devora Schiff
,
Jairo Sierra
,
Lumeng J Yu
,
Atif Khan
,
Bruce Haffty
,
James S Goydos
,
Suzie Chen
ABSTRACT
Gain of function of the neuronal receptor, metabotropic glutamate receptor 1 (Grm1), was sufficient to induce melanocytic transformation in vitro and spontaneous melanoma development in vivo when ectopically expressed in melanocytes. The human form of this receptor, GRM1, has been shown to be ectopically expressed in a subset of human melanomas but not benign nevi or normal melanocytes, suggesting that misregulation of GRM1 is involved in the pathogenesis of certain human melanomas. Sustained stimulation of Grm1 by the ligand, glutamate, is required for the maintenance of transformed phenotypes in vitro and tumorigenicity in vivo. In this study, we investigate the mechanism of an inhibitor of glutamate release, riluzole, on human melanoma cells that express metabotropic glutamate receptor 1 (GRM1). Various in vitro assays conducted show that inhibition of glutamate release in several human melanoma cell lines resulted in an increase of oxidative stress and DNA damage response markers.